Rhofade, Oxymetazoline Cream 1% for the redness of Rosacea
Rhofade is Allergan’s Oxymetazoline based topical treatment for the red face of rosacea. Rhofade is known chemically as a Selective α1-Adrenergic Receptor Agonist, and during the drug’s development was known as AGN-199201 and also V-101.
Recent Rosacea Blog Posts
Good news to start 2017, and as predicted, the FDA has approved Allergan’s RHOFADE. Yes they are going to use uppercase and scream RHOFADE at us everytime we see the product name. Allergan says that RHOFADE will be available for commercial supply starting May 2017 in the United States. Allergan Announces FDA Approval Of RHOFADE […]
In the coming months you will see more and more references to Rhofade. When a new rosacea treatment launches everyone wants to know what is it ? Asking this question makes sense as we normally only find out the name of a product right at the end of the development process. What we now know […]
One little pearl from the Allergan investor presentation is that the company is expecting Rhofade to be approved by the FDA in early 2017. Allergan Plc (AGN) Brenton L. Saunders on Q2 2016 Results – Earnings Call Transcript Aug. 8, 2016 2:03 PM ET About: Allergan plc (AGN) William J. Meury – Chief Commercial Officer […]
Allergan has confirmed that their Oxymetazoline based treatment due to be released in 2017 will be known as Rhofade. The brand name was confirmed in Allergan’s presentation to investors – Allergan plc Q2 2016 Earnings Presentation – Investor Relations, via the slide shown above. Business analysts are already commenting on their predictions for Rhofade’s success […]
In a document prepared for Allergan’s November 4, 2015 R&D Day presentation, Allergan is highlighting the development of its soon to be approved oxymetazoline 1% cream for rosacea. The slides relating to Oxymetazoline show the features of this product, along with other products in development, that Allergan wants to promote to investors. In the presentation […]
